Search Results 1951-1960 of 16588 for Maximum

  1. A Study Using a New Drug, Nivolumab, in Combination With Chemotherapy Drugs to Treat a Type of Cancer Called Nasopharyngeal Carcinoma (NPC) - Mayo Clinic

    ... Maximum serum creatinine (mg/dL) 1 month to \< 6 months: 0.4 mg/dL (male); 0.4 mg/dL (female) 6 months to \< 1 year: 0.5 mg/dL (male); 0.5 mg/dL (female) 1 ...

  2. Pediatric rhabdomyosarcoma: Research and new treatment options - Mayo Clinic

    Many of these children have often reached their maximum dose of radiotherapy, or parents hope to avoid whole-abdominal radiotherapy due to the known and often ...

  3. Clinical trials - Oncology (Medical)

    The purpose of this study is to assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) ...

  4. Gastroenterology and Hepatology - Clinical trials

    Difference in gastric emptying (T1/2, emptying at 2h and emptying at 4h);; Volume to fullness (sensation of usual postprandial fullness) and maximum feeling of ...

  5. Clinical trials - Oncology (Medical)

    The primary objectives are to determine the maximum tolerated dose (MTD) or highest protocol-defined dose (HPDD); in the absence of exceeding the MTD of ...

  6. Clinical trials - Oncology (Medical)

    The purpose of this study is to assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) ...

  7. Lipogems-processed Microfragmented Adipose Tissue Compared to Saline for the Treatment of Knee Osteoarthritis - Mayo Clinic

    ... Maximum Tolerable Dose according to the respective manufacturer's instructions on dose and duration, or their physician's over-riding guidance. Patients who ...

  8. A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) - Mayo Clinic

    The maximum time allowed from establishment of CR1 to registration is 12 months. Participant has presence of the FLT3/ITD activating mutation in the BM or ...

  9. Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation - Mayo Clinic

    The study includes a dose escalation phase to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) and an expansion phase ...

  10. Study to Evaluate CCS1477 in Haematological Malignancies - Mayo Clinic

    When p300 is inhibited, this drives synthetic lethality leading to apoptosis/cell death. This study will determine the maximum tolerated dose (MTD) and/or ...